LINC00162 confers sensitivity to 5-Aza-2′-deoxycytidine via modulation of an RNA splicing protein, HNRNPH1

No abstract is available for this paper.

• Publication year

  2019

• Venue

  Oncogene

• Publication date

  2019-03-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41388-019-0792-8PMID 30914798
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gastric adenocarcinoma

  2017cited by this paper
• Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

  2017cited by this paper
• Long Noncoding RNA PICSAR Promotes Growth of Cutaneous Squamous Cell Carcinoma by Regulating ERK1/2 Activity.

  2016cited by this paper
• Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials

  2016cited by this paper
• Establishment of a DNA methylation marker to evaluate cancer cell fraction in gastric cancer

  2016cited by this paper
• TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

  2016cited by this paper
• S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.

  2016cited by this paper
• Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response

  2016cited by this paper
• Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment

  2016cited by this paper
• Long Noncoding RNAs in Cancer Pathways.

  2016cited by this paper
• Downregulation of miR-320a/383-sponge-like long non-coding RNA NLC1-C (narcolepsy candidate-region 1 genes) is associated with male infertility and promotes testicular embryonal carcinoma cell proliferation

  2015cited by this paper
• MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ*

  2015cited by this paper
• KRAS Genomic Status Predicts the Sensitivity of Ovarian Cancer Cells to Decitabine.

  2015cited by this paper
• A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis.

  2015cited by this paper
• A recombinant reporter system for monitoring reactivation of an endogenously DNA hypermethylated gene.

  2014cited by this paper
• MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors.

  2014cited by this paper
• The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer

  2014cited by this paper
• A Methylation-Based Regulatory Network for MicroRNA 320a in Chemoresistant Breast Cancer

  2014cited by this paper
• ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis

  2014cited by this paper
• Clinical development of demethylating agents in hematology.

  2014cited by this paper
• Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers.

  2013cited by this paper
• Prevention of Helicobacter pylori–Induced Gastric Cancers in Gerbils by a DNA Demethylating Agent

  2013cited by this paper
• Unique Transcriptome Patterns of the White and Grey Matter Corroborate Structural and Functional Heterogeneity in the Human Frontal Lobe

  2013cited by this paper
• FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect

  2013cited by this paper
• A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.

  2013cited by this paper
• Methylation Subtypes and Large-Scale Epigenetic Alterations in Gastric Cancer

  2012cited by this paper
• Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells.

  2012cited by this paper
• NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

  2011cited by this paper
• Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.

  2011cited by this paper
• Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells.

  2010cited by this paper
• Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.

  2010cited by this paper
• S110, a 5-Aza-2′-Deoxycytidine–Containing Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo and Can Reduce Tumor Growth

  2010cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• Epigenetics in cancer.

  2008cited by this paper
• The epigenomics of cancer.

  2007cited by this paper
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

  2007cited by this paper
• Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

  2006cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006cited by this paper
• Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.

  2006cited by this paper
• Heterogeneous Nuclear Ribonucleoprotein F/H Proteins Modulate the Alternative Splicing of the Apoptotic Mediator Bcl-x*

  2005cited by this paper
• Detection and interpretation of altered methylation patterns in cancer cells

  2005cited by this paper
• Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

  2004cited by this paper
• Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.

  2003cited by this paper
• 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy

  2002cited by this paper
• Negative Feedback Loop of Wnt Signaling through Upregulation of Conductin/Axin2 in Colorectal and Liver Tumors

  2002cited by this paper
• Helicobacter pylori infection and the development of gastric cancer.

  2001cited by this paper
• Helicobacter pylori infection and the development of gastric cancer.

  2001cited by this paper
• The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer.

  2001cited by this paper
• Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

  2000cited by this paper
• Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer.

  1997cited by this paper
• Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation.

  1994cited by this paper
• Cellular differentiation, cytidine analogs and DNA methylation.

  1980cited by this paper
• Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice.

  1968cited by this paper

• A novel long non-coding RNA, PICSAR, promotes thyroid cancer progression through the hsa-miR-320A/hsa-miR-485/RAPGEFL1 axis

  2025cites this paper
• Epigenetic disruption of adipogenic gene enhancers in dedifferentiated liposarcomas and its therapeutic value

  2025cites this paper
• Molecular mechanisms of non-genetic aberrant peptide production in cancer

  2024cites this paper
• HNRNPH1 stabilizes FLOT2 mRNA in a non-canonical m6A-dependent manner to promote malignant progression in nasopharyngeal carcinoma

  2024cites this paper
• Aberrant alternative splicing in cancer: Splicing events and their regulatory mechanisms (Review).

  2024cites this paper
• Epigenetics and alternative splicing in cancer: old enemies, new perspectives.

  2024cites this paper
• DNMT1-mediated demethylation of lncRNA MEG3 promoter suppressed breast cancer progression by repressing Notch1 signaling pathway

  2022cites this paper
• RNA-binding proteins as drivers of AML and novel therapeutic targets

  2022cites this paper
• Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance

  2022cites this paper
• The role of alternative splicing in human cancer progression.

  2021cites this paper
• Methylation and Noncoding RNAs in Gastric Cancer: Everything Is Connected

  2021cites this paper
• Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation

  2021cites this paper
• HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway

  2021cites this paper
• HNRNPH1 Is a Novel Regulator Of Cellular Proliferation and Disease Progression in Chronic Myeloid Leukemia

  2021cites this paper
• lnc-NLC1-C inhibits migration, invasion and autophagy of glioma cells by targeting miR-383 and regulating PRDX-3 expression.

  2021cites this paper
• Prediction of tissue origin of adenocarcinomas in the esophagogastric junction by DNA methylation

  2021cites this paper
• The mechanistic role of long non-coding RNAs in advanced prostate cancer response to therapy

  2020cites this paper
• LncRNA HORAS5 promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism.

  2020cites this paper
• Epigenetic priming sensitizes gastric cancer cells to irinotecan and cisplatin by restoring multiple pathways

  2019cites this paper